Drug Profile
Abexinostat - Xynomic Pharmaceuticals
Alternative Names: Abexinostat hydrochloride; CG-781; CRA-024781; CRA-024781 HCl; CRA-024781-01; PCI-24781; PCI-24781-01; S 78454; S78454-1Latest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Developer GSK; Janssen Inc; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Pharmacyclics; Servier; University of California at San Francisco; Xynomic Pharmaceuticals
- Class Amides; Antineoplastics; Benzofurans; Dimethylamines; Hydroxamic acids; Phenyl ethers; Small molecules
- Mechanism of Action Histone deacetylase inhibitors; Rad51 recombinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Renal cell carcinoma
- Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
- Phase I/II Non-Hodgkin's lymphoma; Sarcoma
- Phase I Glioma
- No development reported Breast cancer; Myelodysplastic syndromes; Nasopharyngeal cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 30 Nov 2023 Xynomic Pharmaceuticals completes a phase Ib trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03590054)
- 26 Jun 2023 Phase-I clinical trials in Glioma (Recurrent, Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05698524)
- 26 Jan 2023 Xynomic Pharmaceuticals plans a phase I trial for Glioma (Recurrent, Combination therapy, Late-stage disease, Second-line therapy or greater) (NCT05698524)